Canada · Delayed Price · Currency is CAD Kane Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The company has refocused on wound care, expanding its revyve product platform and distribution network, with clinical evidence supporting efficacy in challenging wounds. Commercial momentum is building, supported by new partnerships, a planned capital raise, and targeted expansion into Europe and military channels.
Fiscal Year 2025
-
Major milestones include the sale of STEM Animal Health, commercial launch of Revive gel, and the pending FB Dermatology acquisition. 2025 objectives focus on clinical trials, expanding distribution, and achieving cash flow positivity, with significant revenue growth expected.
Fiscal Year 2024
-
Q3 2024 saw a dramatic revenue increase driven by the first commercial sales of Revive wound gel and new service revenues, while net loss narrowed significantly year-over-year. Strategic acquisitions, regulatory milestones, and a CAD 3 million private placement position the company for further growth.
-
Q2 2024 saw a major gain from the STEM Animal Health sale, driving net income to CAD 9.2 million and enabling debt repayment. Revenue and gross profit rose year-over-year, while regulatory and distribution progress for Revive and DispersinB signal strong future growth.